IntelGenx antidepressant gets FDA nod, but no launch yet

IntelGenx Technologies has FDA approval in hand for its high-dose antidepressant. Now what? For now, not much. The company can't launch the drug--still known by its CPI-300 code name--until it has a marketing partner. And that isn't expected to happen till the second quarter of next year.

The product is a formulation of Bupropion hydrochloride, the active ingredient in Wellbutrin XL, that allows a 450 mg dose in a single tablet. Biovail, which markets Wellbutrin, only sells 300 mg and 150 mg pills. It has tried to develop a 450 mg version, but hasn't succeeded. Biovail also tried to thwart IntelGenx's efforts with a patent suit, but the smaller company won that fight.

About 10% of Wellbutrin XL prescriptions are for a 450 mg daily dose, IntelGenx CEO Horst Zerbe told BioMed Reports, which requires patients to take two different-strength pills, creating the potential for compliance problems and accidental overdosing. "This would increase the risk of a seizure almost tenfold," Zerbe said. IntelGenx has said that there's a $150 million-plus market right now for a 450 mg pill.

The company says it's in "active licensing discussions with several leading generic and specialty pharmaceutical companies." It says it expects a commercialization deal soon. It already has in hand a manufacturing deal with Pillar5 Pharma.

- see the release from IntelGenx

- read the BioMedReports story

- get more from Reuters

Related Article:
Third Rock bets $35M on upstart Sage Therapeutics in risky CNS market

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.